IR-820 (New Indocyanine Green): Applied Protocols for In Vivo Imaging and Tissue Quantification

Introduction and Principle Overview

Near-infrared (NIR) fluorescence imaging has become an essential tool for real-time, non-invasive mapping of biological processes in living organisms. Among contrast agents, IR-820 (New Indocyanine Green) is gaining prominence due to its stable fluorescence, strong absorption in the NIR region, and favorable pharmacokinetics for vascular and tumor imaging. Provided by APExBIO, IR-820 offers researchers a solid-state dye (molecular weight 849.47, C₄₆H₅₀ClN₂NaO₆S₂) that enables high-sensitivity detection and quantification of diseased tissues in vivo.

By leveraging its spectral properties, IR-820 acts as both a vascular imaging agent and a tumor imaging dye, facilitating precise visualization of tissue perfusion, lesion boundaries, and dynamic biological events. Its compatibility with standard NIR laser excitation (e.g., 808 nm) and emission windows minimizes background autofluorescence and allows for deep tissue penetration.

Step-by-Step Workflow: Maximizing IR-820 Performance

Applied successfully, IR-820 can transform experimental imaging in preclinical models. Below is a robust workflow, with protocol enhancements at each stage:

1. Preparation and Solubilization: Weigh IR-820 under desiccated conditions. Dissolve in sterile phosphate-buffered saline (PBS) or DMSO at concentrations between 1–5 mg/mL. Prepare fresh solutions immediately prior to use, as recommended in the product information.
2. Animal Injection: Administer intravenously via tail vein at 2–10 mg/kg body weight, depending on imaging depth and sensitivity requirements. For vascular imaging, start at the lower end of this range; for tumor imaging, higher doses may enhance contrast.
3. Imaging Acquisition: Initiate imaging 10–30 minutes post-injection. Use an NIR-compatible imaging system (excitation 780–808 nm, emission 820–850 nm). Acquire serial images to capture dye distribution and clearance kinetics.
4. Data Analysis: Quantify fluorescence intensity within regions of interest. Normalize signal against background tissues and calibrate using standards or reference phantoms if absolute quantification is required.

Protocol Parameters

• IR-820 solution preparation: Dissolve IR-820 at 5 mg/mL in sterile PBS or DMSO; filter-sterilize using a 0.22 μm filter; use within 1 hour of preparation.
• Dosage for mouse imaging: Inject 5 mg/kg body weight intravenously, in a total volume of 100–200 μL per mouse.
• Imaging system settings: Set excitation wavelength to 808 nm; emission filter at 830 ± 10 nm; acquire images every 5 min for the first 30 min post-injection.

Advanced Applications and Comparative Advantages

IR-820's spectral profile and in vivo stability make it a superior alternative to traditional dyes for several applications:

• Vascular Imaging: The strong NIR fluorescence of IR-820 enables real-time visualization of blood pool dynamics, vessel integrity, and angiogenesis in small animal models. Its low background signal improves contrast for subtle vascular defects.
• Tumor Imaging and Tissue Quantification: As a tumor imaging dye, IR-820 accumulates preferentially in areas of leaky vasculature, allowing for accurate delineation of tumor margins and assessment of therapeutic response. Quantitative analysis of signal intensity can be directly correlated with diseased tissue burden, as shown in studies modeling tumor progression and treatment efficacy.
• Photothermal and Immunotherapeutic Research: IR-820's properties parallel those of classic indocyanine green (ICG) dyes used in synergistic nanomedicine approaches. For instance, similar NIR dyes have been loaded into metal–organic framework (MOF) nanoparticles for photothermal therapy and immune modulation, as demonstrated in the featured reference study.

Key Innovation from the Reference Study

The reference study by Hao et al. (2023) describes the encapsulation of indocyanine green within GSH-responsive MOF nanoparticles, co-functionalized with a PD-1 inhibitory polypeptide (AUNP12). This design enables dual-action photothermal ablation and immune checkpoint blockade in melanoma models. Their workflow included:

• MOF synthesis and functionalization using azide–alkyne click chemistry for AUNP12 attachment.
• Encapsulation of NIR dye (ICG) to enable photothermal heating under 808 nm laser irradiation.
• In vivo demonstration of tumor regression and immune activation post-treatment.

For users of IR-820 (New Indocyanine Green), this method suggests practical avenues for designing multifunctional imaging–therapeutic platforms. Specifically, IR-820 can be incorporated into similar MOF or polymeric nanoparticles, leveraging its stable NIR fluorescence for both imaging and triggered drug delivery. Moreover, the reference workflow highlights the importance of validating dye release and photothermal efficacy under biological reducing conditions (e.g., GSH-triggered environments).

Troubleshooting and Optimization Tips

• Low Signal or Rapid Clearance: Ensure dye concentration is within the recommended range (2–10 mg/kg). Prepare fresh solutions to avoid photobleaching or degradation. For extended imaging, consider encapsulation in nanoparticles to prolong circulation time, as demonstrated in the reference study.
• High Background or Autofluorescence: Use NIR-compatible filters and verify animal background fluorescence before injection. IR-820 minimizes background, but tissue autofluorescence can still confound results if filter sets are suboptimal.
• Precipitation or Poor Solubility: Dissolve IR-820 in DMSO before dilution with PBS if solubility is an issue. Always filter-sterilize to remove particulates prior to injection.
• Batch Variability: Source IR-820 from a trusted supplier like APExBIO to ensure consistent purity and spectral properties.
• Photostability: Protect IR-820 solutions from light during preparation and storage; work under dimmed conditions and use amber tubes when possible.

Interlinking with Related Research and Resources

Researchers looking to expand their NIR imaging toolkit may wish to consult articles such as:

• The GSH responsive indocyanine green loaded PD-1 inhibitory polypeptide AUNP12 modified MOF nanoparticles for photothermal and immunotherapy of melanoma (complements this guide by providing a detailed example of NIR dye-loaded nanoparticle therapeutics).
• Near-Infrared Dyes in Preclinical Imaging (extends the discussion by reviewing a broader portfolio of NIR dye technologies, including spectral comparisons and tips for multiparametric imaging).
• Tumor Imaging Contrast Agents: Mechanisms and Applications (contrasts IR-820 with alternative imaging agents, highlighting scenarios where its properties offer a technical edge).

Future Outlook and Research Implications

The findings from Hao et al. (2023) and ongoing advances in nanomedicine signal a paradigm shift in how NIR dyes like IR-820 (New Indocyanine Green) are applied. Beyond conventional imaging, their integration into smart delivery vehicles and photothermal agents opens new frontiers for combined diagnosis and therapy. However, translation to clinical practice will require rigorous validation of safety, biocompatibility, and scalable synthesis routes.

For now, IR-820 remains a research-exclusive reagent, but its unique blend of deep tissue penetration, low background, and compatibility with emerging theranostic platforms ensures it will remain a mainstay in preclinical vascular and tumor imaging. APExBIO continues to support this innovation by providing high-quality, well-characterized IR-820 for cutting-edge research worldwide.